Cantor Fitzgerald Analysts Lift Earnings Estimates for KALV

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at Cantor Fitzgerald raised their FY2026 EPS estimates for KalVista Pharmaceuticals in a research report issued on Monday, July 14th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the specialty pharmaceutical company will post earnings per share of ($2.83) for the year, up from their previous estimate of ($2.90). The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same quarter last year, the company earned ($1.07) EPS.

Other equities analysts have also recently issued reports about the stock. Leerink Partners lifted their price objective on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, July 7th. Jones Trading reaffirmed a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright lifted their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, JMP Securities lifted their price objective on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Tuesday, July 8th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Buy” and an average target price of $26.29.

KalVista Pharmaceuticals Trading Up 1.4%

NASDAQ:KALV opened at $16.01 on Wednesday. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $16.32. The firm has a fifty day simple moving average of $12.82 and a 200 day simple moving average of $11.42. The stock has a market capitalization of $799.70 million, a PE ratio of -4.34 and a beta of -0.04.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Boxer Capital Management LLC bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $13,467,000. Octagon Capital Advisors LP bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $11,604,000. Frazier Life Sciences Management L.P. boosted its holdings in KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after acquiring an additional 1,200,000 shares during the last quarter. Stempoint Capital LP bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $8,409,000. Finally, Vestal Point Capital LP boosted its holdings in KalVista Pharmaceuticals by 19.3% in the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock valued at $40,402,000 after acquiring an additional 770,000 shares during the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the transaction, the insider owned 106,611 shares in the company, valued at $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the business’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total value of $517,440.51. Following the sale, the chief executive officer owned 369,595 shares in the company, valued at approximately $5,798,945.55. This trade represents a 8.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,878 shares of company stock valued at $723,617. 10.50% of the stock is owned by insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).